Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 15.53%, which has investors questioning if this is right time to buy.

Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to ...

CTX stems from a genetic mutation in the CYP27A1 gene, resulting in a deficiency of an enzyme essential for lipid breakdown. This deficiency disrupts bile acid production in the liver, preventing ...

A new consensus paper provides an updated evaluation of reference bone turnover markers (BTMs) and newer markers in the ...

Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily Stimulant Medication to Treat ADHD Over the Entire Active Day KANSAS CITY, Kan.

In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025$17.5 million increase in ...

CTX Active Learning focuses on activating organizational values to transform culture for improved performanceAtlanta, March ...

Mirum Pharma's Ctexli has become the first FDA-approved therapy for cerebrotendinous xanthomatosis (CTX), an ultra-rare form of lipid storage disease. Ctexli (chenodiol) has been cleared to treat ...

GM has notified dealers about the recall as of March 6, 2025, and plans to begin notifying owners on April 21, 2025. Owners of the affected models are advised to contact their local GM dealership to ...